Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial

BACKGROUND: Endothelial Progenitor cells (EPCs) has been shown to be dysfunctional in both type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) leading to poor regeneration of endothelium and renal perfusion. EPCs have been shown to be a robust cardiovascular disease (CVD) risk indicator...

Descripción completa

Detalles Bibliográficos
Autores principales: Awal, Hassan B., Nandula, Seshagiri Rao, Domingues, Cleyton C., Dore, Fiona J., Kundu, Nabanita, Brichacek, Beda, Fakhri, Mona, Elzarki, Adrian, Ahmadi, Neeki, Safai, Shauna, Fosso, Magan, Amdur, Richard L., Sen, Sabyasachi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271387/
https://www.ncbi.nlm.nih.gov/pubmed/32493344
http://dx.doi.org/10.1186/s12933-020-01046-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271387/
https://www.ncbi.nlm.nih.gov/pubmed/32493344
http://dx.doi.org/10.1186/s12933-020-01046-z

Ejemplares similares